

RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 25 JUNE 2025

Number of shares comprising the share capital: 15,174,125

Number of shares with voting rights: 14,830,415

Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,173,125

That means a quorum of 88.83% of the 14,830,415 shares with voting rights: <u>the Ordinary Annual General Meeting was able to deliberate</u>.

The Ordinary Annual General Meeting was held on Wednesday, 25 June 2025 at 5:30 p.m. at the Company's headquarters and approved the separate parent company and consolidated financial statements for the 2024 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

	Resolutions	Results of the votes
•	RESOLUTION ONE Approval of the annual financial statements	Resolution adopted by: - 13,170,684 votes in favour - 0 vote against - 2,441 abstentions
	RESOLUTION TWO Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement	Resolution adopted by: - 12,831,312 votes in favour - 339,266 votes against - 2,547 abstentions
•	RESOLUTION THREE Approval of the consolidated financial statements	Resolution adopted by: - 13,170,684 votes in favour - 0 vote against - 2,441 abstentions
•	RESOLUTION FOUR Appropriation of earnings, setting the dividend	Resolution adopted by: - 13,138,631 votes in favour - 34,494 votes against - 0 abstention
•	RESOLUTION FIVE Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code	Resolution adopted by (*): - 13,101,211 votes in favour - 59,549 votes against - 12,365 abstentions



RESOLUTION SIX Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2024 and mentioned in Article L. 22-10-9 of the French Commercial Code	Resolution adopted by: - 12,507,815 votes in favour - 665,242 votes against - 68 abstentions
RESOLUTION SEVEN Approval of the components of compensation paid in 2024 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors	Resolution adopted by: - 13,115,547 votes in favour - 57,510 votes against - 68 abstentions
 RESOLUTION EIGHT Approval of the components of compensation paid in 2024 to Mr. Denis SUPPLISSON, Chief Executive Officer 	Resolution adopted by: - 10,782,118 votes in favour - 2,390,939 votes against - 68 abstentions
 RESOLUTION NINE Approval of the components of compensation paid in 2024 to Mr. Grégoire DE ROTALIER, Deputy CEO 	Resolution adopted by: - 10,782,118 votes in favour - 2,390,939 votes against - 68 abstentions
 RESOLUTION TEN Approval of the components of compensation paid in 2024 to Mr. Damien VALICON, Deputy CEO (non-Board member), as from 01/04/2024 	Resolution adopted by: - 10,762,253 votes in favour - 2,410,804 votes against - 68 abstentions
 RESOLUTION ELEVEN Approval of the compensation policy for Mr. Thierry CHAPUSOT, Chairman of the Board of Directors, for 2025 	Resolution adopted by: - 13,115,547 votes in favour - 57,510 votes against - 68 abstentions
 RESOLUTION TWELVE Approval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer, for 2025 	Resolution adopted by: - 10,545,572 votes in favour - 2,454,875 votes against - 172,678 abstentions
 RESOLUTION THIRTEEN Approval of the compensation policy for Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2025 	Resolution adopted by: - 10,537,207 votes in favour - 2,463,240 votes against - 172,678 abstentions
 RESOLUTION FOURTEEN Approval of the compensation policy for Mr. Damien VALICON, Deputy Chief Executive Officer, for 2025 	Resolution adopted by: - 10,537,207 votes in favour - 2,463,240 votes against - 172,678 abstentions
RESOLUTION FIFTEEN Approval of the compensation policy for Directors	Resolution adopted by: - 13,127,845 votes in favour - 45,212 votes against - 68 abstentions



•	RESOLUTION SIXTEEN Setting total annual compensation for Directors for 2025	Resolution adopted by: - 13,127,845 votes in favour - 45,212 votes against - 68 abstentions
-	RESOLUTION SEVENTEEN Authorisation by the Company to repurchase its own shares	Resolution adopted by: - 11,297,178 votes in favour - 1,875,947 votes against - 0 abstention
•	RESOLUTION EIGHTEEN Powers for formalities	Resolution adopted by: - 13,173,125 votes in favour - 0 vote against - 0 abstention

^(*) After deduction of excluded voting rights

Upcoming financial communications

- 31 July 2025: Q2 2025 revenue After the close of trading
- 26 September 2025: H1 2025 results: 26 September 2025

About Equasens Group

Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1.300 people across Europe.

Equasens Group's specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as data hosting, financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "Technology for a More Human Experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient and secure healthcare system.



Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable Included in the Euronext Tech Leaders segment and the European Rising Tech label



Eligible for the Deferred Settlement Service ("Service à Réglement Différé" - SRD) and equity savings accounts invested in small and mid-caps (PEA-PME).

ISIN: FR 0012882389 - Ticker Code: EQS

Get all the news about Equasens Group <u>www.equasens.com</u> and on <u>LinkedIn</u>

CONTACTS

EQUASENS Group

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique Schmidt Tel: +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com

Financial communications agency:

FIN'EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 - i.aprile@finextenso.fr